Susan J. Ramus

ORCID: 0000-0003-0005-7798 · 57 papers in corpus
2025
The Journal of Pathology ·doi:10.1002/path.6407

Mucinous ovarian carcinoma (MOC) is a rare histotype of epithelial ovarian cancer. Its origins are obscure: while many mucinous tumours in the ovary are metastases from the gastrointestinal tract, MOC can occur as an ovarian primary; howeve…

2025
Gynecologic Oncology ·doi:10.1016/j.ygyno.2025.05.013

ObjectiveMany epithelial ovarian cancer (EOC) risk factors relate to sex hormones. The association between these factors and the expression of androgen receptor (AR), estrogen receptor-α (ER), and progesterone receptor (PR) in tumors is unk…

other 2025
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology ·doi:10.1158/1055-9965.EPI-24-1143

BACKGROUND: Ovarian high-grade serous carcinomas (HGSC) comprise four distinct molecular subtypes based on mRNA expression patterns, with differential survival. Understanding risk factor associations is important to elucidate the etiology o…

2024
American journal of human genetics ·doi:10.1016/j.ajhg.2024.04.011

To identify credible causal risk variants (CCVs) associated with different histotypes of epithelial ovarian cancer (EOC), we performed genome-wide association analysis for 470,825 genotyped and 10,163,797 imputed SNPs in 25,981 EOC cases an…

2023
JAMA network open ·doi:10.1001/jamanetworkopen.2023.0666

ImportanceFrequent aspirin use is associated with reduced ovarian cancer risk, but it is unknown whether genetic factors modify this association. Understanding effect modifiers is important given that any use of aspirin for ovarian cancer c…

preprint 2023
·doi:10.1158/1055-9965.c.6515916

AbstractBackground: Comorbidities can affect survival of ovarian cancer patients by influencing treatment efficacy. However, little evidence exists on the association between individual concurrent comorbidities and prognosis in ovarian canc…

preprint 2023
·doi:10.1158/1055-9965.c.6515916.v1

AbstractBackground: Comorbidities can affect survival of ovarian cancer patients by influencing treatment efficacy. However, little evidence exists on the association between individual concurrent comorbidities and prognosis in ovarian canc…

other 2023
Gynecologic Oncology ·doi:10.1016/j.ygyno.2022.10.018

OBJECTIVE: The presence of macroscopic residual disease after primary cytoreductive surgery (PCS) is an important factor influencing survival for patients with high-grade serous ovarian cancer (HGSC). More research is needed to identify fac…

2023
Journal of the National Cancer Institute ·doi:10.1093/jnci/djad011

BackgroundThe role of ovulation in epithelial ovarian cancer (EOC) is supported by the consistent protective effects of parity and oral contraceptive use. Whether these factors protect through anovulation alone remains unclear. We explored …

2023
The journal of pathology. Clinical research ·doi:10.1002/cjp2.311

Our objective was to test whether p53 expression status is associated with survival for women diagnosed with the most common ovarian carcinoma histotypes (high-grade serous carcinoma [HGSC], endometrioid carcinoma [EC], and clear cell carci…

2023
Clinical cancer research : an official journal of the American Association for Cancer Research ·doi:10.1158/1078-0432.ccr-22-3815

PurposeEndometrioid ovarian carcinoma (ENOC) is the second most-common type of ovarian carcinoma, comprising 10%-20% of cases. Recently, the study of ENOC has benefitted from comparisons to endometrial carcinomas including defining ENOC wit…

2022
Journal of medical genetics ·doi:10.1136/jmedgenet-2021-107904

BackgroundEpithelial tubo-ovarian cancer (EOC) has high mortality partly due to late diagnosis. Prevention is available but may be associated with adverse effects. A multifactorial risk model based on known genetic and epidemiological risk …

2022
Journal of the National Cancer Institute ·doi:10.1093/jnci/djac160

BackgroundKnown risk alleles for epithelial ovarian cancer (EOC) account for approximately 40% of the heritability for EOC. Copy number variants (CNVs) have not been investigated as EOC risk alleles in a large population cohort.MethodsSingl…

other 2022
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology ·doi:10.1158/1055-9965.EPI-21-0977

BACKGROUND: There is suggestive evidence that inflammation is related to ovarian cancer survival. However, more research is needed to identify inflammation-related factors that are associated with ovarian cancer survival and to determine th…

meta-analysis 2022
Journal of Clinical Oncology ·doi:10.1200/jco.21.01900

PURPOSE: Frequent aspirin use has been associated with reduced ovarian cancer risk, but no study has comprehensively assessed for effect modification. We leveraged harmonized, individual-level data from 17 studies to examine the association…

2022
European journal of human genetics : EJHG ·doi:10.1038/s41431-021-00987-7

Polygenic risk scores (PRS) for epithelial ovarian cancer (EOC) have the potential to improve risk stratification. Joint estimation of Single Nucleotide Polymorphism (SNP) effects in models could improve predictive performance over standard…

2021
Journal of the National Cancer Institute ·doi:10.1093/jnci/djaa099

BackgroundParity is associated with decreased risk of invasive ovarian cancer; however, the relationship between incomplete pregnancies and invasive ovarian cancer risk is unclear. This relationship was examined using 15 case-control studie…

preprint 2021
·doi:10.1101/2021.09.16.21262993

Abstract ARID1A (BAF250a) is a component of the SWI/SNF chromatin modifying complex, plays an important tumor suppressor role, and is considered prognostic in several malignancies. However, in ovarian carcinomas there are contradictory repo…

article 2021
The Journal of Pathology ·doi:10.1002/path.5849

Abstract ARID1A (BAF250a) is a component of the SWI/SNF chromatin modifying complex, plays an important tumour suppressor role, and is considered prognostic in several malignancies. However, in ovarian carcinomas there are contradictory rep…

2020
British journal of cancer ·doi:10.1038/s41416-020-0900-0

BackgroundPTEN loss is a putative driver in histotypes of ovarian cancer (high-grade serous (HGSOC), endometrioid (ENOC), clear cell (CCOC), mucinous (MOC), low-grade serous (LGSOC)). We aimed to characterise PTEN expression as a biomarker …

other 2020
European journal of epidemiology ·doi:10.1007/s10654-020-00682-9

While childbearing protects against risk of epithelial ovarian cancer (EOC), few studies have explored the impact on maternal EOC risk of sex of offspring, which may affect the maternal environment during pregnancy. We performed a pooled an…

article 2020
·doi:10.17615/bbtw-kf09

To investigate the association between self-reported endometriosis and the putative functional promoter +331C/T single nucleotide polymorphism (SNP) and the PROGINS allele.

2019
Cancer research ·doi:10.1158/0008-5472.can-17-3864

Genome-wide association studies have identified 40 ovarian cancer risk loci. However, the mechanisms underlying these associations remain elusive. In this study, we conducted a two-pronged approach to identify candidate causal SNPs and asse…

2019
Clinical cancer research : an official journal of the American Association for Cancer Research ·doi:10.1158/1078-0432.ccr-18-3720

PurposeOvarian cancer is a heterogeneous disease that can be divided into multiple subtypes with variable etiology, pathogenesis, and prognosis. We analyzed DNA methylation profiling data to identify biologic subgroups of ovarian cancer and…

other 2018
The journal of pathology. Clinical research ·doi:10.1002/cjp2.109

We aimed to validate the prognostic association of p16 expression in ovarian high-grade serous carcinomas (HGSC) and to explore it in other ovarian carcinoma histotypes. p16 protein expression was assessed by clinical-grade immunohistochemi…